Fc receptor‐like A promotes malignant behavior in renal cell carcinoma and correlates with tumor immune infiltration
Cancer Medicine · 2024
DOI: 10.1002/cam4.70072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jun-Peng Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Medical Scientific Research Foundation of Guangdong Province, The National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Our study aims to investigate the mechanisms through which Fc receptor‐like A (FCRLA) promotes renal cell carcinoma (RCC) and to examine its significance in relation to tumor immune infiltration. Materials and Methods The correlation between FCRLA and data clinically related to RCC was explored using The Cancer Genome Atlas (TCGA), then validated using Gene Expression Omnibus (GEO) gene chip data. Enrichment and protein–protein interaction (PPI) network analyses were performed for FCRLA and its co‐expressed genes. FCRLA was knocked down in RCC cell lines to evaluate its impact on biological behavior. Then the potential downstream regulators of FCRLA were determined by western blotting, and rescue experiments were performed for verification. The relevance between FCRLA and various immune cells was analyzed through GSEA, TIMER, and GEPIA tools. TIDE and ESTIMATE algorithms were used to predict the effect of FCRLA in immunotherapy.
Results
Fc receptor‐like A was associated with clinical and T stages and could predict the M stage (AUC = 0.692) and 1–3‐ and 5‐year survival rates (AUC = 0.823, 0.834, and 0.862) of RCC patients. Higher expression of FCLRA predicted an unfavorable overall survival (OS) in TCGA‐RCC and GSE167573 datasets ( p = 0.03, p = 0.04). FCRLA promoted the malignant biological behavior of RCC cells through the pERK1/2/‐MMP2 pathway and was associated with tumor immune microenvironment in RCC.
Conclusion
Fc receptor‐like A is positively correlated with poor outcomes in RCC patients and plays an oncogenic role in RCC through the pERK1/2‐MMP2 pathway. Patients with RCC might benefit from immunotherapy targeting FCRLA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
- Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Hao Lin
Förderung
- the Medical Scientific Research Foundation of Guangdong Province
- The National Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Liu, J. P., Jiang, Y. F., Liu, J. W., Tian, C. J., Lin, Y. Z., Yang, Y. Z., Zhang, Z. K., Fang, Y. L., Huang, B., & Lin, H. (2024). Fc receptor‐like A promotes malignant behavior in renal cell carcinoma and correlates with tumor immune infiltration. Cancer Medicine. https://doi.org/10.1002/cam4.70072
Vancouver
Liu JP, Jiang YF, Liu JW, Tian CJ, Lin YZ, Yang YZ, et al. Fc receptor‐like A promotes malignant behavior in renal cell carcinoma and correlates with tumor immune infiltration. Cancer Medicine. 2024. doi:10.1002/cam4.70072
BibTeX
@article{Liu2024,
author = {Liu, Jun-Peng and Jiang, Yi-Fan and Liu, Jin-Wen and Tian, Chong-Jiang and Lin, Yu-Zhao and Yang, Yun-Zhi and Zhang, Ze-Ke and Fang, Yi-Liang and Huang, Bin and Lin, Hao},
title = {Fc receptor‐like A promotes malignant behavior in renal cell carcinoma and correlates with tumor immune infiltration},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70072}
}
EUVIMED